Clinical Trials Logo

Eosinophilic Duodenitis clinical trials

View clinical trials related to Eosinophilic Duodenitis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04856891 Completed - Clinical trials for Eosinophilic Gastroenteritis

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis

EoDyssey
Start date: May 20, 2021
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients with active eosinophilic duodenitis. Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of open-label lirentelimab (AK002) through the OLE Period of the study.

NCT ID: NCT04620811 Completed - Clinical trials for Eosinophilic Gastritis

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Start date: December 3, 2020
Phase: Phase 3
Study type: Interventional

This is a Phase 3, open-label, extension study to assess the long term efficacy and safety of lirentelimab given monthly.

NCT ID: NCT04322604 Completed - Clinical trials for Eosinophilic Gastritis

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

ENIGMA 2
Start date: June 18, 2020
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002), given monthly for 6 doses, in patients with moderately to severely active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formerly referred to as Eosinophilic Gastroenteritis) who have an inadequate response with, lost response to, or were intolerant to standard therapies

NCT ID: NCT03664960 Completed - Clinical trials for Eosinophilic Gastroenteritis

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Start date: November 14, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open-label, extension study to assess the safety and tolerability of AK002, given monthly for up to 26 doses.